Evidence map›Paper›PMID 38370774›Full record

ArticlebioRxiv : the preprint server for biology2024

Andi Pan, Charles C Bailey, Tianling Ou, Jinge Xu, Xin Liu, Baodan Hu, Gogce Crynen, Nickolas Skamangas, Naomi Bronkema, Mai Tran and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Andi PanSkaggs Graduate School, Scripps Research, La Jolla, CA 92037, USA.ORCID 0000-0001-5302-9198
Charles C BaileyThe Center for Integrated Solutions to Infectious Diseases, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0003-0200-3523
Tianling OuThe Center for Integrated Solutions to Infectious Diseases, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-5119-2239
Jinge XuThe Center for Integrated Solutions to Infectious Diseases, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Xin LiuThe Center for Integrated Solutions to Infectious Diseases, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-9105-317X
Baodan HuThe Center for Integrated Solutions to Infectious Diseases, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gogce CrynenThe Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.ORCID 0000-0001-6066-9900
Nickolas SkamangasDivision of Infectious Disease, Boston Children's Hospital, Boston, MA 02115, USA.
Naomi BronkemaSkaggs Graduate School, Scripps Research, La Jolla, CA 92037, USA.ORCID 0000-0002-5787-2761
Mai TranDivision of Infectious Disease, Boston Children's Hospital, Boston, MA 02115, USA.
Huihui MuDivision of Infectious Disease, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-7358-368X
Xia ZhangThe Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Yiming YinDivision of Infectious Disease, Boston Children's Hospital, Boston, MA 02115, USA.
Michael D AlpertEmmune Inc., Cambridge, MA 02129, USA.
Wenhui HeThe Center for Integrated Solutions to Infectious Diseases, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Michael FarzanSkaggs Graduate School, Scripps Research, La Jolla, CA 92037, USA.ORCID 0000-0002-2990-5319
Broad Institute · USBoston Children's Hospital · USThe Herbert Wertheim UF Scripps Institute for Biomedical Innovation & TechnologyDecImmune Therapeutics (United States) · US

Funding

Cell and Gene Therapy for HIV CureUM1AI126623 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JEROME, KEITH R, KIEM, HANS-PETER · 2016 to 2020
$24.2M
Project 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING · 2020 to 2024
$14.0M
Therapeutic Use of an Enhanced Form of CD4-IgR37AI091476 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2016 to 2025
$9.2M
An injectable hydrogel platform for sustained release of eCD4-IgR01AI154989 · NIAID · UNIVERSITY OF FLORIDA · PI APPEL, ERIC ANDREW, FARZAN, MICHAEL R. · 2020 to 2024
$4.2M
Engineering CAR-B cells for an HIV-1 functional cureR01DA056771 · NIDA · UNIVERSITY OF FLORIDA · PI Michael R. Farzan · 2022 to 2026
$3.5M
Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apexR21AI152836 · NIAID · SCRIPPS FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2021
$509k
NIAID NIH HHS R01 AI154989NIAID NIH HHS R21 AI152836NIAID NIH HHS R37 AI091476NIAID NIH HHS U19 AI149646NIAID NIH HHS UM1 AI126623NIDA NIH HHS R01 DA056771
6 · The paper itself

Abstract

Many human proteins have been repurposed as biologics for clinical use. These proteins have been engineered with

Identifiers

PMID38370774
PMCPMC10871246
OpenAlexW4391573044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.